Thomas Jefferson University

Michael Mastrangelo

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentMedical Oncology - Thomas Jefferson University
Address1025 Walnut Street
Philadelphia PA 19107
Phone2159558874
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pellegrini C, Cardelli L, Ghiorzo P, Pastorino L, Potrony M, Garc?a-Casado Z, Elefanti L, Stefanaki I, Mastrangelo M, Necozione S, Aguilera P, Rodr?guez-Hern?ndez A, Di Nardo L, Rocco T, Del Regno L, Badenas C, Carrera C, Malvehy J, Requena C, Ba?uls J, Stratigos AJ, Peris K, Menin C, Calista D, Nagore E, Puig S, Landi MT, Fargnoli MC. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium. J Eur Acad Dermatol Venereol. 2023 Dec; 37(12):2498-2508. PMID: 37611275.
      Citations:    
    2. Orloff M, Brennan M, Sato S, Shields CL, Shields JA, Lally S, Mashayekhi A, Mason J, Materin M, Mastrangelo M, Sato T. Unique geospatial accumulations of uveal melanoma. Am J Ophthalmol. 2020 Jul 15. PMID: 32681908.
      Citations:    
    3. Seedor RS, Eschelman DJ, Gonsalves CF, Adamo RD, Orloff M, Amjad A, Sharpe-Mills E, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. Cancers (Basel). 2020 Jan 01; 12(1). PMID: 31906411.
      Citations:    
    4. Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ, Sato T. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017 Dec; 9(16):1323-1330. PMID: 29185395.
      Citations:    
    5. Valsecchi ME, Orloff M, Sato R, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls. Ophthalmology. 2018 Feb; 125(2):210-217. PMID: 28935400.
      Citations:    
    6. Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. J Transl Med. 2017 Jun 23; 15(1):145. PMID: 28645290.
      Citations:    
    7. Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, Kim LJ, Sato T, Kendra KL, Olencki T, Liebner DA, Farrell CJ, Evans JJ, Judy KD, Andrews DW, Dicker AP, Werner-Wasik M, Shi W. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2017 Sep 01; 99(1):22-30. PMID: 28816150.
      Citations:    
    8. Berger AC, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K, Dabbish N, Leiby B, Frank JA, Stitzenberg KB, Meyers MO. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. J Am Coll Surg. 2017 Apr; 224(4):652-659. PMID: 28189663.
      Citations:    
    9. Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol. 2016 Jan; 186(1):43-56. PMID: 26613897.
      Citations:    
    10. Mastrangelo MJ. The Last Chapter. Semin Oncol. 2015 Dec; 42(6):923-4. PMID: 26615137.
      Citations:    
    11. Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M, Sato T. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015 Nov; 2(11):1821-6. PMID: 26870807.
      Citations:    
    12. Feeney KJ, Mastrangelo MJ. Intralesional therapy for in-transit and satellite metastases in melanoma. Surg Oncol Clin N Am. 2015 Apr; 24(2):299-308. PMID: 25769713.
      Citations:    
    13. Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, Berd D, Mastrangelo MJ, Sato T. Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte-Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases. J Vasc Interv Radiol. 2015 Apr; 26(4):523-532.e2. PMID: 25678394.
      Citations:    
    14. Yoshida M, Selvan S, McCue PA, Deangelis T, Baserga R, Fujii A, Rui H, Mastrangelo MJ, Sato T. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res. 2014 Mar; 27(2):297-308. PMID: 24354797.
      Citations:    
    15. Johnson C, Intenzo C, Mastrangelo MJ, Feeney K, Berger AC. Altered drainage patterns in patients with melanoma and previous axillary dissection. J Dermatol. 2013 Jul; 40(7):564-6. PMID: 23594177.
      Citations:    
    16. Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012 Dec; 22(6):440-6. PMID: 23114504.
      Citations:    
    17. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571; PMCID: PMC3338100.
      Citations:    
    18. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011 Dec; 51(2-3):170-82. PMID: 22139852.
      Citations:    
    19. Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, Harigaya K, Sato T. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother. 2012 Feb; 61(2):145-55. PMID: 21853302.
      Citations:    
    20. Berger AC, Fierro M, Kairys JC, Berd D, Sato T, Andrel J, Hyslop T, Mastrangelo MJ. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol. 2012 Jan; 105(1):15-20. PMID: 21815149.
      Citations:    
    21. Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45. PMID: 21519827.
      Citations:    
    22. Berencsi K, Rani P, Zhang T, Gross L, Mastrangelo M, Meropol NJ, Herlyn D, Somasundaram R. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med. 2011 Mar 30; 9:33. PMID: 21450101; PMCID: PMC3076246.
      Citations:    
    23. Nair BC, Williams NC, Cui C, Summers D, Mastrangelo MJ, Hubosky SG, Shields CL, Shields JA, Sato T. Conjunctival melanoma: bladder and upper urinary tract metastases. J Clin Oncol. 2011 Mar 20; 29(9):e216-9. PMID: 21189399.
      Citations:    
    24. de Silva S, Mastrangelo MA, Lotta LT, Burris CA, Izsvák Z, Ivics Z, Bowers WJ. Herpes simplex virus/Sleeping Beauty vector-based embryonic gene transfer using the HSB5 mutant: loss of apparent transposition hyperactivity in vivo. Hum Gene Ther. 2010 Nov; 21(11):1603-13. PMID: 20507234; PMCID: PMC2978550.
      Citations:    
    25. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol. 2010 Sep; 177(3):1422-35. PMID: 20696774.
      Citations:    
    26. Kaplan FM, Mastrangelo MJ, Aplin AE. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J Invest Dermatol. 2010 Nov; 130(11):2669-71. PMID: 20574441.
      Citations:    
    27. Marks JA, Rao AS, Loren D, Witkiewicz A, Mastrangelo MJ, Berger AC. Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater. JOP. 2010; 11(2):173-5. PMID: 20208330.
      Citations:    
    28. Chapman P, Cranmer L, Dixon WG, Hyrich KL, Patterson JR, Symmons DP, Toporcer M, Mastrangelo MJ. The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol. 2010 Feb; 37(1):11-9. PMID: 20172358.
      Citations:    
    29. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009 Jul; 252(1):290-8. PMID: 19561263.
      Citations:    
    30. Mastrangelo MJ. Impact of malignant disease on young adults. Semin Oncol. 2009 Jun; 36(3):193. PMID: 19460576.
      Citations:    
    31. Terai M, Tamura Y, Alexeev V, Ohtsuka E, Berd D, Mastrangelo MJ, Sato T. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother. 2009 Aug; 58(8):1307-17. PMID: 19142637.
      Citations:    
    32. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol. 2008 Dec; 173(6):1768-82. PMID: 18974297.
      Citations:    
    33. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008 Nov 20; 26(33):5436-42. PMID: 18838710.
      Citations:    
    34. Samplaski MK, Rosato EL, Witkiewicz AK, Mastrangelo MJ, Berger AC. Malignant melanoma of the gallbladder: a report of two cases and review of the literature. J Gastrointest Surg. 2008 Jun; 12(6):1123-6. PMID: 18060465.
      Citations:    
    35. Retsas S, Mastrangelo MJ. Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. Semin Oncol. 2007 Dec; 34(6):491-7. PMID: 18083372.
      Citations:    
    36. Solti M, Berd D, Mastrangelo MJ, Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 2007 Aug; 17(4):225-31. PMID: 17625452.
      Citations:    
    37. Mucci T, Long W, Witkiewicz A, Mastrangelo MJ, Rosato EL, Berger AC. Metastatic melanoma causing jejunal intussusception. J Gastrointest Surg. 2007 Dec; 11(12):1755-7. PMID: 17619936.
      Citations:    
    38. Berd D, Mastrangelo MJ, Sato T. Calculation of survival of patients with stage III melanoma. J Clin Oncol. 2005 Dec 20; 23(36):9427; author reply 9428. PMID: 16361644.
      Citations:    
    39. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005 Aug; 15(4):297-304. PMID: 16034309.
      Citations:    
    40. Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1; 22(3):403-15. PMID: 14691123.
      Citations:    
    41. Sato T, Terai M, Yasuda R, Watanabe R, Berd D, Mastrangelo MJ, Hasumi K. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol Immunother. 2004 Jan; 53(1):53-61. PMID: 13680192.
      Citations:    
    42. Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Zhang T, Herlyn DM. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine. 2003 Apr 2; 21(15):1601-12. PMID: 12639481.
      Citations:    
    43. Herlyn D, Birebent B, Akis N, Purev E, Somasundaram R, Mitchell E, Maguire H, Staib L, Mastrangelo M. Colon cancer antigen and anti-idiotype vaccines. Cancer Chemother Biol Response Modif. 2003; 21:287-98. PMID: 15338751.
      Citations:    
    44. Reddy KS, Mastrangelo M, D Johnston T, Khan T, Waid T, McKeown W, Lucas B, Ranjan D. Recipient outcome following living donor kidney transplantation using kidneys procured laparoscopically. Clin Transplant. 2003; 17 Suppl 9:44-7. PMID: 12795668.
      Citations:    
    45. Mastrangelo MJ, Lattime EC. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. 2002 Dec; 9(12):1013-21. PMID: 12522440.
      Citations:    
    46. Manne J, Mastrangelo MJ, Sato T, Berd D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol. 2002 Sep 15; 169(6):3407-12. PMID: 12218163.
      Citations:    
    47. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002 Sep 15; 62(18):5267-72. PMID: 12234995.
      Citations:    
    48. Berd D, Sato T, Mastrangelo MJ. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother. 2002 Aug; 51(6):320-6. PMID: 12111120.
      Citations:    
    49. Berd D, Sato T, Cohn H, Maguire HC, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer. 2001 Nov; 94(4):531-9. PMID: 11745440.
      Citations:    
    50. Gomella LG, Mastrangelo MJ, McCue PA, Maguire HC JR, Mulholland SG, Lattime EC. Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol. 2001 Oct; 166(4):1291-5. PMID: 11547060.
      Citations:    
    51. Birebent B, Koido T, Mitchell E, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai E, Herlyn D. Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients. J Cancer Res Clin Oncol. 2001 Oct; 127 Suppl 2:R27-33. PMID: 11768621.
      Citations:    
    52. Birebent B, Somasundaram R, Purev E, Li W, Mitchell E, Hoey D, Bloom E, Mastrangelo M, Maguire H, Harris DT, Staib L, Braumuller H, Leeser C, Kuttner N, Beger HG, Herlyn D. Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients. Crit Rev Oncol Hematol. 2001 Jul-Aug; 39(1-2):107-13. PMID: 11418307.
      Citations:    
    53. Park AE, Birgisson G, Mastrangelo MJ, Marcaccio MJ, Witzke DB. Laparoscopic splenectomy: outcomes and lessons learned from over 200 cases. Surgery. 2000 Oct; 128(4):660-7. PMID: 11015100.
      Citations:    
    54. Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, Rosato EL, Rosato FE, Sato T. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000 Oct 01; 89(7):1561-8. PMID: 11013372.
      Citations:    
    55. Ejadi S, Rosenblum J, Berd D, McCue P, Mastrangelo M. Diagnostic dilemmas in oncology. Case 1. Melanoma metastatic to the testis. J Clin Oncol. 2000 Sep; 18(17):3187-8. PMID: 10963647.
      Citations:    
    56. Mastrangelo MJ, Eisenlohr LC, Gomella L, Lattime EC. Poxvirus vectors: orphaned and underappreciated. J Clin Invest. 2000 Apr; 105(8):1031-4. PMID: 10772644.
      Citations:    
    57. Nathan FE, Berd D, Sato T, Mastrangelo MJ. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer. 2000 Jan 01; 88(1):79-87. PMID: 10618609.
      Citations:    
    58. Mastrangelo MJ, Maguire HC, Lattime EC. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol. 2000; 465:391-400. PMID: 10810643.
      Citations:    
    59. Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999 Sep-Oct; 6(5):409-22. PMID: 10505851.
      Citations:    
    60. Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, Spitler LE, Mastrangelo MJ. Immunologic approaches to the treatment of prostate cancer. Semin Oncol. 1999 Aug; 26(4):439-47. PMID: 10482186.
      Citations:    
    61. Mastrangelo M. Conference report 3rd International Conference Adjuvant Therapy of Malignant Melanoma. Melanoma Res. 1999 Jun; 9(3):306-8. PMID: 10465588.
      Citations:    
    62. Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol. 1998 Dec; 25(6):646-53. PMID: 9865679.
      Citations:    
    63. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother. 1998 Sep; 47(1):1-12. PMID: 9755873.
      Citations:    
    64. Nathan FE, Mastrangelo MJ. Systemic therapy in melanoma. Semin Surg Oncol. 1998 Jun; 14(4):319-27. PMID: 9588725.
      Citations:    
    65. G?nd?z K, Shields JA, Shields CL, Sato T, Mastrangelo MJ. Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol. 1998 Mar; 125(3):407-9. PMID: 9512169.
      Citations:    
    66. Maguire HC, Berd D, Lattime EC, McCue PA, Kim S, Chapman PB, Mastrangelo MJ. Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters. Cancer Biother Radiopharm. 1998 Feb; 13(1):13-23. PMID: 10850338.
      Citations:    
    67. Alexander AA, Nazarian LN, Capuzzi DM, Rawool NM, Kurtz AB, Mastrangelo MJ. Color Doppler sonographic detection of tumor flow in superficial melanoma metastases: histologic correlation. J Ultrasound Med. 1998 Feb; 17(2):123-6. PMID: 9527572.
      Citations:    
    68. Nazarian LN, Alexander AA, Kurtz AB, Capuzzi DM, Rawool NM, Gilbert KR, Mastrangelo MJ. Superficial melanoma metastases: appearances on gray-scale and color Doppler sonography. AJR Am J Roentgenol. 1998 Feb; 170(2):459-63. PMID: 9456964.
      Citations:    
    69. McClay EF, Berd D, Mastrangelo MJ. The Dartmouth Regimen: gone or going strong? Cancer Invest. 1998; 16(6):421-3. PMID: 9679534.
      Citations:    
    70. Mastrangelo MJ, Sato T, Lattime EC, Maguire HC, Berd D. Cellular vaccine therapies for cancer. Cancer Treat Res. 1998; 94:35-50. PMID: 9587681.
      Citations:    
    71. Sato T, Bullock TN, Eisenlohr LC, Mastrangelo MJ, Berd D. Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clin Immunol Immunopathol. 1997 Dec; 85(3):265-72. PMID: 9400626.
      Citations:    
    72. Berd D, Maguire HC, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 1997 Jun; 15(6):2359-70. PMID: 9196151.
      Citations:    
    73. Nathan FE, Berd D, Sato T, Shield JA, Shields CL, De Potter P, Mastrangelo MJ. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res. 1997 Jun; 16(2):201-8. PMID: 9261748.
      Citations:    
    74. Sorensen SC, Garc?a-Manero G, Mastrangelo MJ, Soltan A. Does lymph node dissection still have a role in cancer therapy? Semin Oncol. 1997 Jun; 24(3):xxxiii-xxxiv, xxxix, xli-xlii, xlv. PMID: 9208880.
      Citations:    
    75. Sato T, Babazono A, Shields JA, Shields CL, De Potter P, Mastrangelo MJ. Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest. 1997; 15(2):98-105. PMID: 9095204.
      Citations:    
    76. Mastrangelo MJ, Maguire HC, Sato T, Nathan FE, Berd D. Active specific immunization in the treatment of patients with melanoma. Semin Oncol. 1996 Dec; 23(6):773-81. PMID: 8970602.
      Citations:    
    77. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res. 1996 Aug; 2(8):1383-90. PMID: 9816311.
      Citations:    
    78. Berd D, Mastrangelo MJ, Lattime E, Sato T, Maguire HC. Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol Immunother. 1996 Jun; 42(5):263-7. PMID: 8706046.
      Citations:    
    79. Nazarian LN, Alexander AA, Rawool NM, Kurtz AB, Maguire HC, Mastrangelo MJ. Malignant melanoma: impact of superficial US on management. Radiology. 1996 Apr; 199(1):273-7. PMID: 8633159.
      Citations:    
    80. Ohta M, Berd D, Shimizu M, Nagai H, Mastrangelo M, Shields JA, Shields CL, Croce CM, Huebner K. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer. 1996 Mar 15; 65(6):762-7. PMID: 8631588.
      Citations:    
    81. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol. 1996 Feb; 23(1):88-100. PMID: 8607035.
      Citations:    
    82. Mastrangelo MJ, Berd D, Nathan FE, Lattime EC. Gene therapy for human cancer: an essay for clinicians. Semin Oncol. 1996 Feb; 23(1):4-21. PMID: 8607031.
      Citations:    
    83. Nathan FE, Mastrangelo MJ. Adjuvant therapy for cutaneous melanoma. Semin Oncol. 1995 Dec; 22(6):647-61. PMID: 8539640.
      Citations:    
    84. Somasundaram R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, Marks G, Kane M, Mastrangelo M, Herlyn D. Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol. 1995 Sep 15; 155(6):3253-61. PMID: 7673738.
      Citations:    
    85. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother. 1995 Sep; 41(3):151-6. PMID: 7553683.
      Citations:    
    86. Berd D, Mastrangelo MJ. Combination chemotherapy of metastatic melanoma. J Clin Oncol. 1995 Mar; 13(3):796-7. PMID: 7884439.
      Citations:    
    87. Sato T, Maguire HC, Mastrangelo MJ, Berd D. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin Immunol Immunopathol. 1995 Jan; 74(1):35-43. PMID: 7994925.
      Citations:    
    88. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 1994 Oct 15; 54(20):5269-72. PMID: 7923152.
      Citations:    
    89. Berd D, Maguire HC, Mastrangelo MJ, Murphy G. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother. 1994 Sep; 39(3):141-7. PMID: 7923243.
      Citations:    
    90. Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res. 1994 Jul 01; 54(13):3325-8. PMID: 8012943.
      Citations:    
    91. Herlyn D, Somasundaram R, Zaloudik J, Jacob L, Harris D, Kieny MP, Sears H, Mastrangelo M. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys. 1994; 24-25:143-53. PMID: 7736518.
      Citations:    
    92. Berd D, Maguire HC, Mastrangelo MJ. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann N Y Acad Sci. 1993 Aug 12; 690:147-52. PMID: 8368733.
      Citations:    
    93. McLaughlin C, Maguire HC, Mastrangelo MJ. Natural history of a superficial spreading melanoma. Int J Dermatol. 1993 Apr; 32(4):293-6. PMID: 8486463.
      Citations:    
    94. McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992 Feb 20; 50(4):553-6. PMID: 1537621.
      Citations:    
    95. Harris DT, Mastrangelo MJ. Theory and application of early systemic therapy. Semin Oncol. 1991 Dec; 18(6):493-503. PMID: 1775968.
      Citations:    
    96. Berd D, Murphy G, Maguire HC, Mastrangelo MJ. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 1991 May 15; 51(10):2731-4. PMID: 2021952.
      Citations:    
    97. Slovin SF, Maguire HC, Mastrangelo MJ. The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro. Cancer. 1990 Dec 15; 66(12):2541-6. PMID: 2123415.
      Citations:    
    98. McLean IW, Berd D, Mastrangelo MJ, Shields JA, Davidorf FH, Grever M, Makley TA, Gamel JW. A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. Am J Ophthalmol. 1990 Nov 15; 110(5):522-6. PMID: 2240139.
      Citations:    
    99. Schultz S, Kane M, Roush R, Miller V, Berd D, Goldman L, Mastrangelo M. Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanoma. Surg Gynecol Obstet. 1990 Nov; 171(5):393-7. PMID: 2237723.
      Citations:    
    100. Berd D, Maguire HC, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990 Nov; 8(11):1858-67. PMID: 2230873.
      Citations:    
    101. Cardi G, Mastrangelo MJ, Berd D. Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res. 1989 Dec 01; 49(23):6562-5. PMID: 2479465.
      Citations:    
    102. Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res. 1989 Dec 01; 49(23):6840-4. PMID: 2582430.
      Citations:    
    103. Turner BJ, Siatkowski RM, Augsburger JJ, Shields JA, Lustbader E, Mastrangelo MJ. Other cancers in uveal melanoma patients and their families. Am J Ophthalmol. 1989 Jun 15; 107(6):601-8. PMID: 2729409.
      Citations:    
    104. Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin Oncol. 1989 Jun; 16(3):230-53. PMID: 2658084.
      Citations:    
    105. Harris DT, Mastrangelo MJ. Serotherapy of cancer. Semin Oncol. 1989 Jun; 16(3):180-98. PMID: 2658082.
      Citations:    
    106. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer. 1989 Apr 01; 63(7):1292-5. PMID: 2920358.
      Citations:    
    107. Schultz S, Mastrangelo MJ. The pathophysiology and staging of cutaneous malignant melanoma. Semin Oncol. 1989 Feb; 16(1 Suppl 1):27-33. PMID: 2645653.
      Citations:    
    108. Mastrangelo MJ, Schultz S, Kane M, Berd D. Newer immunologic approaches to the treatment of patients with melanoma. Semin Oncol. 1988 Dec; 15(6):589-94. PMID: 3061011.
      Citations:    
    109. Mc Clay EF, Mastrangelo MJ. Systemic chemotherapy for metastatic melanoma. Semin Oncol. 1988 Dec; 15(6):569-77. PMID: 2462747.
      Citations:    
    110. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 1988 Mar 15; 48(6):1671-5. PMID: 2830969.
      Citations:    
    111. Berd D, Mastrangelo MJ. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest. 1988; 6(3):337-49. PMID: 3167614.
      Citations:    
    112. Berd D, Mastrangelo MJ. Elimination of immune suppressor mechanisms in humans by oxazaphosphorines. Methods Find Exp Clin Pharmacol. 1987 Sep; 9(9):569-77. PMID: 2963936.
      Citations:    
    113. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res. 1987 Jun 15; 47(12):3317-21. PMID: 2953413.
      Citations:    
    114. Slovin SF, Lackman RD, Mastrangelo MJ. HLA-A2 in sarcomas: an immunobiologic perspective. Transplantation. 1987 Jun; 43(6):923-5. PMID: 3495915.
      Citations:    
    115. Berd D, Mastrangelo MJ. Depletion of suppressor-cytotoxic T-lymphocytes by administration of a murine monoclonal antibody. Cancer Res. 1987 May 15; 47(10):2727-32. PMID: 2952261.
      Citations:    
    116. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep. 1987 May; 71(5):465-9. PMID: 3567970.
      Citations:    
    117. McClay E, Lusch CJ, Mastrangelo MJ. Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep. 1987 Feb; 71(2):219-20. PMID: 3802121.
      Citations:    
    118. Slovin SF, Lackman RD, Ferrone S, Kiely PE, Mastrangelo MJ. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol. 1986 Nov 01; 137(9):3042-8. PMID: 3093588.
      Citations:    
    119. Mastrangelo MJ, Berd D, Maguire H. The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol. 1986 Jun; 13(2):186-94. PMID: 2940686.
      Citations:    
    120. Berd D, Maguire HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986 May; 46(5):2572-7. PMID: 3697996.
      Citations:    
    121. Goldman LI, Elder D, Clark WH, Mastrangelo MJ, Stennett J. Assessment of survival rates with metastatic malignant melanomas. Surg Gynecol Obstet. 1986 Mar; 162(3):199-203. PMID: 3952612.
      Citations:    
    122. Donoso LA, Berd D, Augsburger JJ, Mastrangelo MJ, Shields JA. Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol. 1985 Jun; 103(6):796-8. PMID: 4004617.
      Citations:    
    123. Berd D, Maguire HC, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res. 1984 Nov; 44(11):5439-43. PMID: 6488195.
      Citations:    
    124. Berd D, Maguire HC, Mastrangelo MJ. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res. 1984 Mar; 44(3):1275-80. PMID: 6229330.
      Citations:    
    125. Mastrangelo MJ, Berd D, Maguire HC. Current condition and prognosis of tumor immunotherapy: a second opinion. Cancer Treat Rep. 1984 Jan; 68(1):207-19. PMID: 6362864.
      Citations:    
    126. Donoso LA, Nagy RM, Brockman RJ, Augsburger JJ, Shields JA, Berd D, Mastrangelo MJ. Metastatic uveal melanoma. Hepatic cell-surface enzymes, isoenzymes, and serum sialic acid levels in early metastatic disease. Arch Ophthalmol. 1983 May; 101(5):791-4. PMID: 6847471.
      Citations:    
    127. Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H. Augmentation of the human immune response by cyclophosphamide. Cancer Res. 1982 Nov; 42(11):4862-6. PMID: 7127320.
      Citations:    
    128. Berd D, Mastrangelo MJ. Differential sensitivity of two murine leukaemia sublines to cytolysis by Corynebacterium parvum-activated macrophages. Br J Cancer. 1981 Dec; 44(6):819-27. PMID: 7326193.
      Citations:    
    129. Herlyn M, Clark WH, Mastrangelo MJ, Guerry DP, Elder DE, LaRossa D, Hamilton R, Bondi E, Tuthill R, Steplewski Z, Koprowski H. Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res. 1980 Oct; 40(10):3602-9. PMID: 6159966.
      Citations:    
    130. Augsburger JJ, Shields JA, Mastrangelo MJ, Frank PE. Diffuse primary malignant melanoma after prior primary cutaneous malignant melanoma. Arch Ophthalmol. 1980 Jul; 98(7):1261-4. PMID: 7396780.
      Citations:    
    131. Berd D, Wilson EJ, Bellet RE, Mastrangelo MJ. Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma. Cancer Res. 1979 Nov; 39(11):4472-6. PMID: 387215.
      Citations:    
    132. Bellet RE, Danna V, Mastrangelo MJ, Berd D. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents. J Natl Cancer Inst. 1979 Nov; 63(5):1185-8. PMID: 91697.
      Citations:    
    133. Berkelhammer J, Mastrangelo MJ, Bellet RE, Berd D, Prehn RT. Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients. Eur J Cancer (1965). 1979 Feb; 15(2):197-204. PMID: 436896.
      Citations:    
    134. Bellet RE, Catalano RB, Mastrangelo MJ, Berd D. Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea. Cancer Treat Rep. 1978 Dec; 62(12):2095-9. PMID: 751717.
      Citations:    
    135. Berkelhammer J, Mastrangelo MJ, Bellet RE, Prehn RT, Thibault LH. Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy. Eur J Cancer (1965). 1978 Jul; 14(7):793-7. PMID: 658104.
      Citations:    
    136. Clark WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol. 1978 May; 114(5):732-8. PMID: 646394.
      Citations:    
    137. Bellet RE, Catalno RB, Mastrangelo MJ, Berd D, Koons LS. Phase II trial of VM-26 in patients with metastatic malignant melanoma. Cancer Treat Rep. 1978 Mar; 62(3):445-7. PMID: 348313.
      Citations:    
    138. Greene MH, Reimer RR, Clark WH, Mastrangelo MJ. Precursor lesions in familial melanoma. Semin Oncol. 1978 Mar; 5(1):85-7. PMID: 635599.
      Citations:    
    139. Bellet RE, Catalano RB, Mastrangelo MJ, Berd D. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma. Med Pediatr Oncol. 1978; 4(1):11-5. PMID: 75498.
      Citations:    
    140. Bellet RE, Vaisman I, Mastrangelo MJ, Lustbader E. Multiple primary malignancies in patients with cutaneous melanoma. Cancer. 1977 Oct; 40(4 Suppl):1974-81. PMID: 907999.
      Citations:    
    141. Laucius JF, Patel YA, Lusch CJ, Koons LS, Bellet RE, Mastrangelo MJ. The phase II evaluation of Bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma. Med Pediatr Oncol. 1977; 3(3):237-42. PMID: 618010.
      Citations:    
    142. Clark WH, Mastrangelo MJ, Ainsworth AM, Berd D, Bellet RE, Bernardino EA. Current concepts of the biology of human cutaneous malignant melanoma. Adv Cancer Res. 1977; 24:267-338. PMID: 322460.
      Citations:    
    143. Bellet RE, Engstrom PF, Catalano RB, Creech RH, Mastrangelo MJ. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep. 1976 Sep; 60(9):1395-7. PMID: 1016973.
      Citations:    
    144. Bellet RE, Catalano RB, Danna VG, Berd DA, Berkelhammer J, Mastrangelo MJ. A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma. J Clin Pharmacol. 1976 Aug-Sep; 16(8-9):433-8. PMID: 787016.
      Citations:    
    145. Pliskin ME, Mastrangelo MJ, Bellet R, Berkelhammer J. BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case. Oral Surg Oral Med Oral Pathol. 1976 Jul; 42(1):73-9. PMID: 781579.
      Citations:    
    146. Bellett RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat Rep. 1976 May; 60(5):595-600. PMID: 791478.
      Citations:    
    147. Ainsworth AM, Clark WH, Mastrangelo M, Conger KB. Primary malignant melanoma of the urinary bladder. Cancer. 1976 Apr; 37(4):1928-36. PMID: 1260695.
      Citations:    
    148. Bodurtha AJ, Berkelhammer J, Kim YH, Laucius JF, Mastrangelo MJ. A clinical histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission. Cancer. 1976 Feb; 37(2):735-42. PMID: 943226.
      Citations:    
    149. Mastrangelo MJ, Sulit HL, Prehn LM, Bornstein RS, Yarbro JW, Prehn RT. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer. 1976 Feb; 37(2):684-92. PMID: 766947.
      Citations:    
    150. Pliskin ME, Mastrangelo MJ, Brown AM, Custer RP. Metastatic melanoma of the maxilla presenting as a gingival swelling. Oral Surg Oral Med Oral Pathol. 1976 Jan; 41(1):101-4. PMID: 1061028.
      Citations:    
    151. Mastrangelo MJ, Berd D, Bellet RE. Critical review of previously reported clinical trials of cancer immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci. 1976; 277(00):94-123. PMID: 793490.
      Citations:    
    152. Sieper WJ, Mastrangelo MJ, Belle RE. Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma. Cancer Chemother Rep. 1975 Nov-Dec; 59(6):1181-2. PMID: 769962.
      Citations:    
    153. Berkelhammer J, Mastrangelo MJ, Laucius JF, Bodurtha AJ, Prehn RT. Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors. Int J Cancer. 1975 Oct 15; 16(4):571-8. PMID: 51835.
      Citations:    
    154. Mastrangelo MJ, Bellet RE, Berkelhammer J, Clark WH. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer. 1975 Oct; 36(4):1305-8. PMID: 1175129.
      Citations:    
    155. Creech RH, Catalano RB, Mastrangelo MJ, Engstrom PF. An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. Cancer. 1975 Apr; 35(4):1101-7. PMID: 1116103.
      Citations:    
    156. Bodurtha AJ, Chee DO, Laucius JF, Mastrangelo MJ, Prehn RT. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res. 1975 Jan; 35(1):189-93. PMID: 1109788.
      Citations:    
    157. Mastrangelo MJ, Laucius JF, Outzen HC. Fundamental concepts in tumor immunology: a brief review. Semin Oncol. 1974 Dec; 1(4):291-5. PMID: 4620436.
      Citations:    
    158. Laucius JF, Bodurtha AJ, Mastrangelo MJ, Creech RH. Bacillus Calmette-Guerin in the treatment of neoplastic disease. J Reticuloendothel Soc. 1974 Dec; 16(6):347-73. PMID: 4616079.
      Citations:    
    159. Bodurtha A, Kim YH, Laucius JF, Donato RA, Mastrangelo MJ. Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer. Am J Clin Pathol. 1974 Jun; 61(6):747-52. PMID: 4598826.
      Citations:    
    160. Bellet RE, Mastrangelo MJ, Dixon LM. Letter: ICRF 159. Lancet. 1974 May 11; 1(7863):926. PMID: 4133440.
      Citations:    
    161. Bellet RE, Mastrangelo MJ, Engstrom PF, Strawitz JG, Weiss AJ, Yarbro JW. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816). Cancer Chemother Rep. 1974 Mar-Apr; 58(2):217-22. PMID: 4133839.
      Citations:    
    162. Mastrangelo MJ, Kim YH, Bornstein RS, Chee DO, Sulit HL, Yarbro JW, Prehn RT. Clinical and histologic correlation of melanoma regression after intralesional BCG therapy: a case report. J Natl Cancer Inst. 1974 Jan; 52(1):19-24. PMID: 4590009.
      Citations:    
    163. Bornstein RS, Mastrangelo MJ, Sulit H, Chee D, Yarbro JW, Prehn LM, Prehn RT. Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr. 1973 Dec; 39:213-20. PMID: 4595320.
      Citations:    
    164. Mastrangelo MJ, Grage TB, Bellet RE, Weiss AJ. A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. Cancer. 1973 May; 31(5):1170-5. PMID: 4705155.
      Citations:    
    165. Bellet RE, Mastrangelo MJ, Dixon LM, Yarbro JW. Phase I study of ICRF-159 (NSC-129943) in human solid tumors. Cancer Chemother Rep. 1973 Apr; 57(2):185-9. PMID: 4742498.
      Citations:    
    166. Bellet RE, Mastrangelo MJ, Engstrom PF, Custer RP. Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study). Neoplasma. 1973; 20(3):303-9. PMID: 4125219.
      Citations:    
    167. Mastrangelo MJ, Chee DO, Sulit H, Engstrom PF. Malignant melanoma. Pa Med. 1972 Oct; 75(10):43. PMID: 4643953.
      Citations:    
    168. Weiss AJ, Stambaugh JE, Mastrangelo MJ, Laucius JF, Bellet RE. Phase I study of 5-azacytidine (NSC-102816) . Cancer Chemother Rep. 1972 Jun; 56(3):413-9. PMID: 19051503.
      Citations:    
    169. Weiss AJ, Mastrangelo MJ. Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease. Cancer Chemother Rep. 1970 Apr; 54(2):109-11. PMID: 4946000.
      Citations:    
    Mastrangelo's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (525)
    Explore
    _
    Co-Authors (45)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _